

bodies—Conditions for reconstitution of dimeric IFN- γ ".
 Eur. J. Biochem., 215:481-486 (1993).
 Welch, "How Cells Respond to Stress", Scientific American,
 pp. 56-64 (May 1993).
 5 Wetzel (1994) Trends Biochem. 12, 193-198.
 Wetzel et al., (1991) Bio/Technol. 9, 731-737.
 Winter et al., (1994) J. Biol. Chem. 269, 22007-22013.
 Wisniewski et al., Biochem. Biophys. Res. Commun.,
 192:359-365 (1993)
 0 Yankner et al., (1990) Science 250, 279-282.
 Young et al., (1994).
 Zhu et al., (1989) Nature 339, 483-484.

✓ What is claimed is:

- 5 ✓ 1. A method of selecting an anti-aggregation molecule having the chaperone-like activity of anti-aggregation, wherein the anti-aggregation molecule is selected from the group consisting of a monoclonal antibody, a genetically engineered antibody antigen binding fragment, and a single chain monoclonal antibody, and wherein said anti-aggregation molecule binds to a bioactive native target polypeptide epitope with a high binding constant and is non-inhibitory to the biological activity of the target polypeptide comprising the steps of:
 - 15 denaturing a target polypeptide which aggregates.
 - mixing the target polypeptide with said anti-aggregation molecule to form a mixture.
 - incubating the mixture under conditions allowing for aggregation.
 - 10 selecting non-aggregated mixtures, and
 - testing the nonaggregated target polypeptide coupled to the anti-aggregation molecule for bioactivity thereby selecting an anti-aggregation molecule with the chaperone-like activity of anti-aggregation which when coupled to the target polypeptide maintains bioactivity.
 - 15 2. The method of claim 1 further characterized by the target polypeptide being β -amyloid.
 - ✓ 3. A method of selecting an anti-aggregation molecule
 - 10 having the chaperone-like activity of anti-aggregation, wherein the anti-aggregation molecule is selected from the group consisting of a monoclonal antibody, a genetically engineered antibody antigen binding fragment, and a single chain monoclonal antibody, and wherein said anti-aggregation molecule binds to a bioactive native target polypeptide epitope with a high binding constant, reverses aggregation and is non-inhibitory to the biological activity of the target polypeptide comprising the steps of:
 - 20 preparing an aggregated target polypeptide.
 - mixing the target polypeptide with said anti-aggregation molecule to form a mixture.
 - selecting mixtures with non-aggregated target polypeptides, and
 - 15 testing the target polypeptide coupled to the anti-aggregation molecule for bioactivity thereby identifying an anti-aggregation molecule with the chaperone-like activity of anti-aggregation which when coupled to the target polypeptide maintains bioactivity.
 - 20 4. The method of claim 3 further characterized by the target polypeptide being β -amyloid.

* * * * *

add A1
Add B1

65911 "0411450